CanSino Biologics, a Chinese vaccine firm became the world's first company on March 16 to start a clinical trial study of potential Coronavirus vaccine. Within 10 weeks, the firm again achieves a milestone by sharing peer-reviewed data assessing the safety and immunogenicity of a SARS-CoV-2 vaccine, beating US firm Moderna, which did not share such data.